Drug Discovery
ByIs Pierre Fabre’s US Cell‑Therapy Comeback Bid a Signal of Regulatory Reset for Rare Diseases?
Pierre Fabre is reviving its US cell‑therapy ambitions, seeking FDA re‑approval for Ebvallo after the agency initially rejected its submission.…
Is Roche’s $480M Bet Making South Korea Asia’s Next Biopharma Powerhouse?
Roche’s $480M Bet on South Korea Signals a Strategic Pivot to Asia’s AI–Oncology Powerhouse Roche has committed $480 million to…
PepGen’s DMD Gene Therapy Hit with FDA Partial Hold—A Warning Sign for Biotech Pipeline Timelines
PepGen’s DMD Gene Therapy Hit with FDA Partial Hold—A Warning Sign for Biotech Pipeline Timelines PepGen’s experimental Duchenne…
Blackstone’s $400M Bet on Teva–Sanofi Gut Drug Signals a Major Shift in the IBD Landscape
Blackstone has invested $400 million into Teva and Sanofi’s experimental ulcerative colitis (UC) and Crohn’s disease therapy, marking one of…
Can Sanofi SA’s $1.2 Billion AI-Driven Autoimmune Alliance with Kali Therapeutics Inc Unlock Next-Gen Tri-Specific Antibody Therapies and Disrupt Immunology Markets?
Key Highlights: AI-Powered Biologics Platforms Accelerate Next-Gen Antibody DiscoverySanofi SA’s licensing agreement with Kali Therapeutics Inc highlights the…
Can Eli Lilly and Company’s “Triple-G” AI-Enabled Next-Gen Drug Deliver 15%+ Weight Loss and Redefine the $100B Obesity-Diabetes Market Dominated by Novo Nordisk A/S?
Key Highlights: AI-Driven Clinical Design Unlocks Superior Metabolic OutcomesEli Lilly and Company’s late-stage trial results for retatrutide highlight…
